This segment focuses on the formulation, development, and manufacturing of soft capsules and oral dosage forms. Catalent provides services for a wide range of products, including prescription drugs, over-the-counter medications, dietary supplements, and animal health products. Research and development activities include optimizing formulations for enhanced bioavailability and controlled release. Technologies employed encompass softgel encapsulation, tablet manufacturing, and advanced coating techniques. The segment serves various therapeutic areas, with a strong emphasis on patient compliance and ease of administration. Market positioning is strong due to the company's extensive experience and diverse technology portfolio. Future opportunities lie in expanding into novel drug delivery systems and personalized medicine. Regulatory and clinical aspects are crucial, with a focus on meeting stringent quality standards and obtaining necessary approvals. Partnerships with pharmaceutical and consumer health companies are key to driving innovation and market access.

The Biologics segment provides comprehensive services for the development and manufacturing of biologic drugs, including cell and gene therapies. This includes cell line development, cell therapy and viral-based gene therapy manufacturing, formulation, development, and manufacturing for parenteral dose forms (vials, prefilled syringes, and cartridges), and analytical development and testing services. Research and development efforts are focused on improving manufacturing processes, enhancing product stability, and developing novel delivery systems for biologics. Technologies include cell culture, fermentation, purification, and aseptic filling. The segment supports a wide range of therapeutic areas, including oncology, immunology, and rare diseases. Catalent's market position is strengthened by its expertise in complex biologics and its ability to provide integrated solutions. Future growth opportunities include expanding capacity for cell and gene therapy manufacturing and developing new bioconjugation technologies. Regulatory and clinical aspects are critical, with a focus on compliance with GMP regulations and successful clinical trial outcomes. Partnerships with biotechnology companies are essential for advancing innovative therapies.

This segment offers formulation, development, and manufacturing services across a range of technologies, along with integrated downstream clinical development and commercial supply solutions. It also provides an oral delivery solutions platform, including pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. Research and development activities focus on improving drug bioavailability, developing modified-release formulations, and creating innovative oral dosage forms. Technologies include advanced formulation techniques, such as lipid-based drug delivery systems and solid dispersion technologies. The segment serves various therapeutic areas, with a focus on improving patient outcomes through enhanced drug delivery. Market positioning is strong due to the company's expertise in oral drug delivery and its ability to provide end-to-end solutions. Future opportunities include expanding into personalized medicine and developing new drug delivery platforms. Regulatory and clinical aspects are crucial, with a focus on meeting regulatory requirements and demonstrating clinical efficacy. Partnerships with pharmaceutical companies are key to driving innovation and commercial success.

This segment provides comprehensive services for clinical trials, including manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics. It also offers FastChain demand-led clinical supply services. Research and development activities focus on optimizing supply chain management, improving packaging technologies, and developing innovative solutions for decentralized clinical trials. Technologies include advanced logistics systems, temperature-controlled storage, and real-time tracking. The segment supports clinical trials across various therapeutic areas, with a focus on ensuring the timely and efficient delivery of investigational products. Catalent's market position is strengthened by its global network and its ability to provide flexible and customized solutions. Future opportunities include expanding into decentralized clinical trials and developing new supply chain technologies. Regulatory and clinical aspects are critical, with a focus on compliance with GMP regulations and ensuring the integrity of clinical trial supplies. Partnerships with pharmaceutical and biotechnology companies are essential for supporting clinical trial programs.